Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9UBC2

UPID:
EP15R_HUMAN

ALTERNATIVE NAMES:
Eps15-related protein

ALTERNATIVE UPACC:
Q9UBC2; A2RRF3; A5PL29; B4DKA3

BACKGROUND:
The protein Epidermal growth factor receptor substrate 15-like 1, alternatively named Eps15-related protein, is integral to the process of receptor-mediated endocytosis. It ensures the efficient internalization of molecules like integrin beta-1 and transferrin receptor, with a dependency on DAB2 for ITGB1 but not TFR, indicating a selective mechanism for cargo internalization.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Epidermal growth factor receptor substrate 15-like 1 unveils potential avenues for therapeutic intervention. By targeting this protein, novel strategies could be developed to manipulate endocytic pathways, offering promising treatments for conditions associated with abnormal cellular material uptake.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.